US-based science and technology company Merck has unveiled a new packaging centre at its headquarters in Darmstadt, Germany, to support its operations.

The company has invested around €63m between 2015 and 2018 for the new centre, which is part of its €1bn investment to transform the Darmstadt site into contemporary global headquarters.

Spread across 15,000m2 of space, the new facility will be used for packaging and shipping of pharma medicines in more than 90 countries.

It will also support patient needs with flagship medicines such as Glucophage for diabetes, Concor for cardiovascular diseases, and Euthyrox for thyroid disorders.

Merck executive board chairman and CEO Stefan Oschmann said: “Darmstadt is our prime hub for the manufacturing of medicines and it plays a key role in our plans for future growth.

“This latest investment in a new state-of-the-art packaging centre reflects our commitment to our headquarters and is a compelling example of how we use the latest technological advances to always better serve our patients.”

“With this investment, Merck is contributing substantially to the great density of innovative and high-performing companies in Hessen.”

“The new production facility in Darmstadt is a gratifying commitment to this location. That Merck is continuing to invest in the place where the company was born 350 years ago and creating new jobs in the process is a good sign for the region.

“With this investment, Merck is contributing substantially to the great density of innovative and high-performing companies in Hessen.”

The packaging plant features eight fully automated packaging lines and robotised logistics, which enable it to process more than 210 million boxes of medicines annually.

It also incorporates various new technologies, including the tracking and tracing of medicines to prevent counterfeit, as well as smart packaging to ensure flexibility in the production of medicines.

The facility will also support the production of the company’s future pharma products such as evobrutinib and tepotinib, which are currently in clinical development.

Free Whitepaper How electronic inspection sensors prevented a potentially extremely costly product recall

A pharmaceutical client was at risk of a product recall due to a capping problem with a new tablet formulation. This document explains how DJA Pharma prevented a costly recall with a simple, elegant and effective solution.

Enter your details here to receive your free whitepaper.

Machinery whitepaper

Download our whitepaper

Yes I have read and accept the terms and conditions and privacy policys.


You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our Verdict Privacy Policy to see how we protect and manage your submitted data.

You will receive your free whitepaper after you submit the form.

Close